Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) FCF Margin (2020 - 2025)

Historic FCF Margin for Pliant Therapeutics (PLRX) over the last 5 years, with Q3 2025 value amounting to 2586.63%.

  • Pliant Therapeutics' FCF Margin changed N/A to 2586.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 6553.57%, marking a year-over-year change of. This contributed to the annual value of 7422.91% for FY2023, which is 64276500.0% down from last year.
  • Pliant Therapeutics' FCF Margin amounted to 2586.63% in Q3 2025.
  • In the past 5 years, Pliant Therapeutics' FCF Margin registered a high of 6148.44% during Q1 2025, and its lowest value of 10226.61% during Q2 2023.
  • For the 4-year period, Pliant Therapeutics' FCF Margin averaged around 618.11%, with its median value being 1120.29% (2021).
  • Its FCF Margin has fluctuated over the past 5 years, first skyrocketed by 6262000bps in 2022, then crashed by -97325300bps in 2023.
  • Quarter analysis of 4 years shows Pliant Therapeutics' FCF Margin stood at 1023.36% in 2021, then tumbled by -56bps to 1598.22% in 2022, then tumbled by -540bps to 10226.61% in 2023, then surged by 125bps to 2586.63% in 2025.
  • Its FCF Margin was 2586.63% in Q3 2025, compared to 5032.76% in Q2 2025 and 6148.44% in Q1 2025.